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Available online 2 July 2013Assessment of immunogenicity is an integral part of product development and involves
evaluation of binding and neutralizing antibodies. The use of cell-based assays for detection of
neutralizing antibodies (NAbs) is usually a regulatory expectation. Different cell-based assay
formats are available for detection of anti-interferon-beta (IFN-β) NAbs but all present technical
difficulties and limitations. In this paper, a non-cell-based NAb assay which overcomes the
limitations of cell-based assays is described. This NAb assay utilizes an electrochemiluminescence
detection platform and is based on the first step involved in all IFN-β-induced biological activities,
namely the binding of IFN-β to its receptor, which is inhibited when NAbs are present. Using this
approach, NAb titers in clinical samples frommultiple sclerosis patients treated with IFN-βwere
determined and compared with those obtained using existing cell-based NAb assays. The
sensitivity of the assays was not comparable, the cell-based approach having superior sensitivity.
However a good correlation between the two approaches was observed. This study illustrates the
practicality and feasibility of non-cell-based neutralization assays in the context of immunoge-
nicity, however the utility of this approach would need to be assessed on a case-by-case basis for
each therapeutic.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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Currently, three innovator IFN-β products have been
developed and approved for treatment of patients with
relapsing-remitting multiple sclerosis (RRMS) in the EU/US.
Avonex (Biogen-IDEC) and Rebif (Merck Serono), formulated
differently, are manufactured using a rDNA-based Chinese
hamster ovary (CHO) cell expression system and are generi-
cally classified as IFN-β-1a. Betaseron (or Betaferon; Bayer), a
rDNA derived IFN-β produced in Escherichia coli, is classified asochemiluminescence;
tein a; NAbs, neutral-
, relapsing-remitting
x: +44 1707 641057.
).
 BY-NC-ND license.IFN-β-1b and has markedly lower specific activity than
IFN-β-1a (Runkel et al., 1998; Karpusas et al., 1998).
A potential consequence of treatment with recombinant
IFN-β is the development of antibodies to the biotherapeutic
(Ross et al., 2000; Goodin, 2005; Sominanda et al., 2007).
Such antibodies are usually IgG and can be either non-
neutralizing or neutralizing (NAbs) (Pachner, 2003; Perini
et al., 2004; Gneiss et al., 2008). The former simply bind to
IFN-β without apparently affecting its intrinsic activity
while the NAbs bind IFN-β molecules in a way that prevents
binding of IFN-β to the cell surface type I IFN-receptors,
thus inhibiting biological activity of IFN-β and reducing
its efficacy. Persistent and high titer of anti-IFN-β NAbs
are associated with reduced pharmacodynamics and loss
of bioactivity (Bertolotto et al., 2003; Scagnolari et al.,
2007; Deisenhammer, 2009). Furthermore, evidence strongly
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NAbs is associated with reduced clinical responses (Perini et
al., 2004; Namaka et al., 2006; Bertolotto, 2009). Since this
has implications for disease management, effective monitor-
ing of the development of anti-IFN-β NAbs is required
(Farrell et al., 2011) and recommendations for clinical use
of data on neutralizing antibodies to IFN-β therapy in MS
have been published by the Neutralizing Antibodies on
Interferon Beta in MS (NABINMS) consortium (Polman et
al., 2010).
IFN-β elicits several biological effects, including antiviral,
antiproliferative and immunomodulatory activities, which
form the basis of methods for measuring the potency of IFN-β
products and for detecting neutralizing antibodies to IFN-β.
Antiviral assays (AVA) in which IFN-β inhibits viral replication
in a dose-dependent fashion are commonly used. Different
aspects of viral replication, including RNA and protein syn-
thesis, cytopathic effect and production of progeny virus, are
quantifiable using different cell–virus combinations (Meager,
2006). Another approach for measuring NAbs is themyxovirus
resistance protein A (MxA) induction assay, which measures
the expression of the IFN-inducible GTPase MxA in cultured
cells. The expression ofMxA is dependent on IFN concentration
andmeasured as secretedMxA protein using an ELISA (Pungor
et al., 1998). Alternatively quantitative reverse transcription-
polymerase chain reaction technology (qPCR) can be used to
determine the levels of specific IFN-induced mRNA, e.g., MxA
mRNA or 6–16 mRNA (Bertolotto et al., 2007; Aarskog et al.,
2009). Such assays require short incubation periods following
addition of IFN and can be completed within a day. The
potential for high throughput applications is increased if
branched DNA technology is used, as gene expression can
then be measured without the requirement for RNA extraction
and cDNA synthesis (Moore et al., 2009). Reporter gene assays
(RGA) have also been described to measure NAbs. In these,
an IFN-responsive cell line is transfected with a plasmid in
which an IFN-inducible promoter controls the expression of an
enzyme which can be measured, often within hours of IFN
stimulation. The IFN-induced enzymatic activity is directly
related to IFN concentration/potency, and the presence of NAbs
inhibits the amount of enzyme produced (Lallemand et al.,
2008; Lam et al., 2008).
The spectrum of cell-based assays available should provide
analysts with the means to accurately measure NAbs to IFN-β.
However variable experimental conditions and the absence of
harmonious methods for calculating titers have led to wide
variations in the reported incidence of patients developingNAbs
and in the measured NAbs titers. This has an impact on the
interpretation of results regarding clinical relevance of NAbs.
To overcome the technical difficulties inherent to cell-based
neutralization assays, we utilized an electrochemiluminescence
detection method, using the MesoScale Discovery (MSD) plat-
form, to develop non-cell-based assays to assess the presence
and nature of anti-IFN-β antibodies. In addition to a screening
assay for binding Abs, we developed and characterized a
non-cell-based assay, based on the binding of IFN-β to its
receptor, to detect and quantify IFN-β NAbs. We present here
the first report of the use of a non-cell-based assay for the
assessment of NAbs in clinical samples from IFN-β treated
patients. Comparative data from this assay and existing cell-
based neutralization assays are also shown.2. Materials and methods
2.1. Serum samples
Patients sera have been grouped into 3 distinct cohorts
(none overlapping), depending on the available serum samples
and the bioassay previously used. Cohort A (n = 46) includes
post-treatment only samples, tested in the MxA protein assay.
Cohort B (n = 10) includes post-treatment only samples,
tested in the antiviral assay. Cohort C (n = 31) includes
sequential samples (baseline and subsequent time-points),
tested in antiviral and reporter gene assays. Pooled or
individual sera from normal healthy donors were also included
in the study (n = 27).
Ethical approval and informed consent from patients and
donors were obtained in accordance with the guidelines in
the Helsinki Declaration for all sera tested.
2.2. Reagents
Therapeutic grade IFN-β-1a preparations were supplied to
NIBSC directly by the manufacturer and routine supply chains.
The recombinant human IFN-α/β R2/Fc chimera was obtained
from R&D Systems (4015-AB) and the recombinant vaccinia
virus-encoded neutralizing type I interferon receptor B18R,
was obtained from eBioscience (14-8185). A lyophilized
pooled human serum sample from IFN-β treated patients
(coded 99/606, available from NIBSC) and a hyperimmune
sheep polyclonal anti-IFN-β serum generated at NIBSC served
as positive controls.
2.3. Protein labeling
IFN-β-1a was biotinylated with EZ-link Sulfo-NHS-LC-Biotin
(Thermo Scientific, 21335). The biotin, resuspended in water,
was mixed with IFN-β to give a molecular challenge ratio of
label/protein of 2 and the mixture left at room temperature for
1 h to enable the labeling reaction to reach completion. The
labeled IFN-β was isolated using a PD-10 desalting column
(GE Healthcare, 52-1308-00 AP), recovered in PBS and stored at
4 °C.
The labeling of IFN-β-1a with ruthenium-NHS-ester was
performed as per manufacturer's instructions. Briefly, the
ruthenium-NHS-ester (labeled Sulfo-Tag, MSD, R91AN-1) was
resuspended in cold distilled water and mixed with IFN-β to
give a molecular challenge ratio of label/protein of 2. The
reaction mixture was incubated for 2 h at room temperature
and the conjugated IFN-β isolated by centrifugation using
Amicon Ultra 3K centrifugal filters (Millipore, UFC800324),
recovered in PBS and stored at 4 °C.
Binding of ruthenium-conjugated IFN-β to immobilized
B18R was evaluated using standard bare plates (MSD,
L15XA-3) coated with B18R in PBS (0.4 μg/ml; 30 μl/well)
overnight at 4 °C. After washing with PBS-0.05% Tween 20, the
wells were blocked with PBS-3%BSA for 1 h at room temper-
ature, the plates washed again and ruthenium-conjugated
IFN-β in PBS-0.5%BSA added to the plates (25 μl/well).
Following incubation at room temperature for a further 2 h,
the plates were washed and read buffer T with surfactant
(MSD, R92TC-2), diluted twofold in water, added to the wells
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MSD SectorImager 2400 analyzer.
2.4. Cell-based assays
2.4.1. Antiviral IFN-β neutralization assays
The assays were performed as previously described
(Meager et al., 2005). Briefly, human glioblastoma cells (2D9,
Daubener et al., 1994) were treated with a diluted IFN-β-1a
preparation that had been pre-incubated for 2 h with serial
dilutions of test sera. The cells were then challenged with
encephalomyocarditis virus for 24 h, stained with 0.05% amido
blue black, fixed with 4% formaldehyde in acetic acid buffer,
and stain eluted with 0.05M NaOH solution before absorbance
was read at 620 nm. Titers were calculated according to
Kawade's formula and expressed in ten-fold reduction unit
per ml (Kawade, 1986; Grossberg et al., 2001).
2.4.2. Reporter gene IFN-β neutralization assays
A transfected HEK 293 cell line containing alkaline phos-
phatase cDNA linked to the interferon stimulated response
element promoter, designated ISRE SEAP 293P, was used as
previously described (LaFleur et al., 2001; Meager et al., 2005;
Meager et al., 2011). Briefly, monolayers were treated with a
diluted IFN-β-1a preparation that had been pre-incubated for
2 h with serial dilutions of test sera. Following incubation at
37 °C for 48 h, aliquots of cell supernatants were transferred
into 96-well microtiter plates and p-nitrophenyl phosphate
(pNPP) substrate added. The plateswere incubated for 3–6 h at
room temperature and the absorbance read at 405 nm. Titers
were calculated as for the antiviral assays (2.4.1).
2.4.3. MxA protein assay
This assay was performed as previously described (Files
et al., 2007). For this, samples were mixed within IFN-β-1a
for 1 h at room temperature prior to incubation with A549
(human embryonic lung cells) for 24 h. Samples were
removed by aspiration and cells were lysed. The MxA protein
in the lysates was measured by ELISA. Titers were calculated
as for the antiviral assays (2.4.1).
2.5. Binding ECL assay
To assess the presence of anti-IFN-β antibodies, dilution
series of test sera were incubated with an equal volume of
biotinylated IFN-β plus ruthenium-conjugated IFN-β (both at
0.1 μg/ml in PBS-0.5% BSA) for 2 h at room temperature in
polypropylene plates. The sample mixtures (25 μl/well) were
then transferred to pre-blocked streptavidin-coated plates
(MSD L15SA-2) and incubated for 2 h. The plates were
washed twice with PBS-0.05% Tween and following addition
of read buffer T diluted twofold in water (150 μl/well) to the
wells, the plates were read in a MSD SectorImager 2400
analyzer.
2.6. Non-cell-based neutralization assay
MSD standard bare plates (MSD L15XA-3) were coated
with B18R in PBS (0.4 μg/ml; 30 μl/well) overnight at 4 °C
then washed with PBS-0.05% Tween. To determine the
neutralizing capacity of anti-IFN-β antibodies, serial dilutionsof test sera were mixed with an equal volume of ruthenium-
conjugated IFN-β (diluted to 20 ng/ml in PBS-0.5% BSA)
in polypropylene plates. Following incubation for 2 h at
room temperature on a rotational shaker, the mixtures were
transferred to the coated plates and incubated for 2 h at room
temperature on a rotational shaker. The plates were washed
twice with PBS-0.05% Tween and following addition of read
buffer T (150 μl/well) to the wells, the plates were read in a
MSD SectorImager 2400 analyzer. The reading buffer was
diluted fourfold to minimize the background.
For each sample a dilution series was included. Neutral-
izing antibody titers were derived from graphical plots of ECL
counts against serum dilution as the reciprocal dilution
yielding a value half-way between the maximum and mini-
mum ECL values.
2.7. Statistical analysis
Inter-assays, inter-plates and intra-assay variability were
assessed by running 3 plates (same samples — different
layouts) repeated on 3 days by the same operator. Statistical
analysis was based on the potencies relative to the lyophi-
lized positive antibody control sample coded 99/606 and was
performed using the CombiStats software (European Direc-
torate for the Quality of Medicines and HealthCare, EDQM).
The correlation coefficients R2 between anti-IFN-β neu-
tralizing antibody titers derived from cell-based assays with
those derived from non-cell-based assays were calculated
using GraphPad Prism™ software version 4.0 (San Diego, CA,
USA), after log10 transformation of the titers.
3. Results
3.1. Binding assays
A bridging assay was developed to enable detection of
anti-IFN-β antibodies in clinical samples from IFN-β treated
RRMS patients. For optimization, different concentrations of
labeled IFN-βwere assessed and a concentration of 0.1 μg/ml
produced optimal response. This concentration was least
susceptible to matrix effects when negative controls (normal
human sera) were tested and provided the highest signal to
noise ratio when a positive control (pooled human sera 99/
606) was assayed, and was therefore used in subsequent
assays. None of the normal human sera (individual or
pooled) analyzed by this assay had pre-existing anti-IFN-β
antibodies. At a dilution of 1/20, the average signal for the
normal human serum samples was 61.5 with a standard
deviation of 11.2 ECL counts (data not shown). The cut-off
limit for the assignment of a positive signal would depend on
the dilution factor and the nature of the individual diseased
serum sample. Therefore, a dilution series has to be assessed
for each individual serum sample to obtain the binding
profiles. Representative binding data for a panel of samples,
including both negative and positive samples, is shown in
Fig. 1A.
Characterization of the binding assays showed that all
assays were valid for linearity and parallelism using ANOVA
tests. The variation between plates within an assay was
assessed by calculating the geometric coefficient of variation,
expressed as a percentage of the assay mean (%GCV) for each
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Fig. 1. Binding (A) and neutralization (B) profiles in ECL assays. Post-treatment serum samples from IFN-β treated patients (cohort B; n = 10) and pooled normal
human sera (nhs) were analyzed for detection of anti-IFN-β antibodies (A) and neutralization potential of detected antibodies (B). Samples 1, 3, 5, 6, 7, 8 and 9
were positive for anti-IFN-β antibodies and the detected antibodies were neutralizing. Pooled normal human sera (nhs) and samples 2, 4 and 10 were negative for
anti-IFN-β antibodies.
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was between 1.6 and 3.4% depending on the nature of the
sample and between 1.9 and 3.7% across samples, depending
on the assay. Between assay variation was assessed by
calculating the GCV, expressed as a percentage of the overall
mean potency per sample over the 3 assays (%GCV), and varied
between 2.2 and 6.7% depending on the sample. The variation
between duplicate samples within a plate and within an assay
is assessed by calculating the root mean square expressed as a
percentage of the mean relative potency for each sample
(RMS%). There was excellent agreement between duplicates of
the positive control antibody; and also between the duplicates
of an antibody positive sample after calculation of the mean
relative potencies over the 3 assays. Thewithin plate variability
as represented by the average % difference between duplicated
sample for the 3 plates per assay is low (1.0 to 4.7%, dependingon the sample and the assay). The low pooled inter-assay %GCV
(4.3%) together with the low values for the inter-plate %GCV
showed a very good reproducibility between plates within an
assay and a very good reproducibility of the bridging assay over
time.
3.2. Non-cell-based neutralization assay
3.2.1. Assay development and characterization
Binding of ruthenium-conjugated IFN-β (diluted in PBS or
pooled normal human sera) to two available forms of IFN-β
receptors was evaluated in presence or absence of neutral-
izing antibody positive control 99/606. The receptors used
were a human recombinant IFN-α/β R2/Fc chimera and the
viral protein B18R, a type I IFN receptor encoded by the
B18R gene of the Western Reserve vaccinia virus strain. As
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Fig. 2. Dose–response curve of ruthenium-conjugated IFN-β diluted in PBS-
0.5% BSA (gray) or pooled human sera 1/100 (white) binding to immobilized
viral protein B18R (0.4 μg/ml) on MSD standard bare plates. The results
shown are the average of duplicates, on 2 plates. 75% (dashed line) of the
maximum binding (straight line) was obtained for a concentration of 20 ng/ml
ruthenium-conjugated IFN-β, which was consequently used as challenge
concentration in the neutralization assays.
41I. Cludts et al. / Journal of Immunological Methods 395 (2013) 37–44expected, the complexity of the interferon receptor present
on mammalian cells, comprising two subunits, is not
mimicked by immobilizing the IFN-α/β R2 alone. Conversely
the B18R protein is sufficient for IFN-β to stably bind to the
cell surface (Colamonici et al., 1995; Alcami et al., 2000) and
was therefore used in subsequent NAb assays. The assay was
optimized by immobilizing increasing concentrations of
B18R and of the tested concentrations the highest signal was
observedwhen 0.4 μg/ml B18Rwas immobilized. In agreement
with the challenge concentrations usually employed in NAb
assays (Wadhwa and Thorpe, 2008), 20 ng/ml of ruthenium-
conjugated IFN-β was used as a challenge concentration as its
response corresponds to 75% of the maximum signal observed
when increasing concentrations of ruthenium-conjugated
IFN-β were allowed to bind to immobilized B18R, as shown in
Fig. 2. We found that standard bare plates allow for a higher
signal to noise ratio at all concentrations of immobilized
receptor in comparison with high bind plates and were
therefore used in subsequent studies.10 20 40 80 160 320
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A
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ts
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Fig. 3. Binding of ruthenium-conjugated IFN-β (20 ng/ml) to immobilized viral prot
positive control human serum 99/606 (at 1/1000 dilution) diluted in normal human
The figure illustrates the absence of serum effects at high concentration of serum sStatistical analysis was based on the potencies relative to
the positive control 99/606 after fitting a 4-parameter dose–
response-curve to the data. The pooled inter-plates %GCV
across assays varied between 18.4 and 20.6% for the positive
control antibody and a high positive sample. Only a low
positive sample showed a higher %GCV, of 38.2%. The pooled
inter-plates %GCV across samples varied between 18.1 and
33.5% depending on the assay. Inter-assays %GCVwas between
5.7 and 23.6% depending on the sample, with a pooled
inter-assay %GCV of 17.3%. There was a good agreement be-
tween the duplicate standards and also between the duplicate
positive samples after calculation of the mean relative poten-
cies over the 3 assays. The intra-plate variability as represented
by the average % difference between duplicated sample for the
3 plates per assay is of a similar order to the inter-plate and
inter-assay variability (between 16.6 and 22.9%, depending on
the sample and the assay). The neutralization assays appear to
have, on average, higher between plates and between assays
variability than the binding assays. Due to the polyclonal
nature of the samples analyzed and to the possible variation
in the efficacy of the B18R immobilization on the plates, some
variability is expected. In view of the inter-plate variation
between assays, a complete dilution curve of the positive
control antibody was run on each plate. Each plate could be
analyzed as a separate assay if the inter-plate variation is too
high.
3.2.2. Analysis of clinical samples
Serum samples from RRMS patients treated with IFN-β
and controls were evaluated for NAbs using optimized assay
procedures. Testing of normal human sera showed that
matrix effects, which can be problematic in cell-based assays,
were minimal in these non-cell-based NAb assay. Normal
human sera did not contain pre-existing neutralizing anti-
IFN-β antibodies. Of the clinical samples tested, all samples
negative for NAbs in cell-based assays were negative in the
non-cell-based assay. Similarly, all samples positive for NAbs
in cell-based assays were positive in the non-cell-based assay,
with the exception of one sample. In none of the assessed
normal human sera or clinical samples did we observe a
significant matrix effect at high concentration of serum. The
effect of dilution of representative normal human sera or
untreated patients' sera on the binding of the neutralizing
antibody positive control 99/606 to B18R is illustrated in Fig. 3.10 20 40 80 160 320
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ts
ein B18R (0.4 μg/ml) on MSD standard bare plate, in presence of neutralizing
sera (A, n = 4) or sera from untreated MS patients from cohort C (B, n = 6).
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Fig. 4. Neutralization curves obtained in the non-cell-based assay for the
positive control serum 99/606 (open squares), pooled normal human sera
(open triangles), and three clinical samples from cohort A: a sample negative
for NAbs (inverted triangles), a sample with low titer of NAbs (titer = 100,
diamonds) and a sample with high titer of NAbs (titer = 1400, circles).
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positive using theMxAprotein assaywere also found to beNAb
positive in the non-cell-based assay. Only one discrepant result
was observed, as a patient serum sample with a very low
titer of neutralizing antibodies in the bioassay could not
be identified as positive in the non-cell-based assay. Fig. 4
illustrates typical neutralization curves obtained for clinical
samples with negative, low titer or high titer of NAbs. The
correlation between the Nab titers obtained in the two types of
assays is high, as R2 = 0.814 after log transformation of the
titers (Fig. 5A).
The assessment of serum samples from cohort B patients
(n = 10) showed that seven of these patients had anti-IFN-β
binding antibodies. All antibody positive samples also
contained neutralizing antibodies (Fig. 1B). For this group
of patients, the correlation coefficient R2 between log10
titers obtained in the non-cell-based NAb assays and those
obtained in an antiviral assay varies between 0.867 and
0.910.
For a selected number of patients (cohort C), sequential
samples (n = 31) were tested in both cell-based and non-
cell-based assays. Results showed that the samples identified
as positive in cell-based assays were also positive in the
non-cell-based NAb assay. The NAbs titers correlated highly
with those obtained either in the antiviral or the reporter0 1 2 3 4 5
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4
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Fig. 5. Correlation between log10 IFN-β NAbs titers as obtained in the non-cell-based
A, n = 46), the reporter gene assay (B) or the antiviral assay (C) (IFN-β treated pagene assay. The correlation factor between log10 titers
obtained in the non-cell-based assay and those obtained in
a reporter gene assay is R2 = 0.938; while the correlation
coefficient between log10 titers obtained in the non-cell-
based assay and those obtained in an antiviral assay is R2 =
0.910 (Fig. 5B & C). Using the binding and the neutralizing
ECL assays to evaluate sequential serum samples from patients
selected on the basis of absence of neutralizing antibodies
in the cell-based assay, we were able to identify a very small
number of patients developing non-neutralizing antibodies.
The binding activity is positive, although low, while no
neutralization is observed in the time course for which we
have samples (Fig. 6).
4. Discussion
It is recognized that NAb assays are an important element of
the assessment of immunogenicity of a biotherapeutic. While
the US draft guidance urges the use of cell-based assays for
determination of NAbs, the European guideline allows the use
of a non-cell-based assay if cell-based assays are not feasible or
available (U.S. Department of Health and Human Services,
2009; EMEA/CHMP/BMWP/14327/2006, 2007) and even rec-
ommend it as a method of choice in some instances (EMEA/
CHMP/BMWP/86289/2010, 2012). Therefore, the comparison
of cell-based and non-cell-based assays for determination of
NAbs during product development and clinical phases, as well
as during post-marketing surveillance, is a much debated
topic. The feasibility of developing non-cell-based NAb assays
has been illustrated previously for detection of neutralizing
auto-antibodies against the cytokine IL-17 in auto-immune
patients (Cludts et al, 2010). A recent publication, in which
different assay formats were compared, showed the potential
of competitive ligand-binding assays for NAb evaluation during
product development, but no clinical data were provided
(Finco et al, 2011).
Here, we have explored the possibility of using a non-
cell-based NAb assay for the assessment of clinical samples
from IFN-β treated RRMS patients. It is recognized that after
treatment with IFN-β, a significant percentage of patients
develop anti-IFN-β antibodies, and that these antibodies are
mostly neutralizing. Although several cell-based assays are
available, the ability to detect and determine the titer of
neutralizing antibodies against IFN-β in non-cell-based assays
would be a useful tool in clinical laboratories as these assays are3 4 5 0 1 2 3 4 5
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Fig. 6. Binding (A) and neutralizing (B) profiles in ECL assays for serum samples from a patient developing non-neutralizing IFN-β antibodies: baseline T0 (open
squares) and subsequent time-points T7 (circles) and T10 (inverted triangles).
43I. Cludts et al. / Journal of Immunological Methods 395 (2013) 37–44easy and quick to perform in comparison with the cell-based
assays which can be technically difficult, time-consuming and
challenging in terms of assay validation. In this study we have
shown the feasibility of a non-cell-based NAb assay based on
the inhibition of binding of IFN-β to its receptor, using the
electrochemiluminescence detection system. Neutralizing an-
tibodies present in the test sample prevent the binding of some
or all ruthenium-conjugated IFN-β to the immobilized receptor
and the assay signal is proportionally reduced. Clinical samples
from IFN-β treated patients were assessed and results were
compared with those obtained in cell-based IFN-β NAb assays.
Since the concentration of IFN-β used as challenge in the
non-cell-based assay is higher than in the cell-based assays, the
magnitude of signals obtained in the non-cell-based assays is
lower and calculated titers are noticeably lesser. The higher
amount of IFN-β used in the non-cell-based assays also impacts
on the sensitivity of the assay. Thismay explain the discrepancy
found for one sample between the two types of assays. While
the sensitivity of the non-cell-based NAb assay may be lower,
the correlation is high between the two approaches. The ability
to screen a great number of samples in a binding assay using
384-well plates allows initial discrimination between anti-
IFN-β antibody positive and negative samples before 96-well
plates are used for NAbs titer-determination analysis. This
set-up could be useful in hospital laboratories formonitoring of
patients or where the ability to perform cell-based assays is
limited. It could also be useful in development and assessment
of biosimilars, when large comparative studies are needed.
Matrix effects at high concentration of serum can be a
limiting factor in bioassays as many sera have growth
promoting activity and/or cytotoxic effects, but there is
minimal impact of the serum concentration in the assays
presented here. The observed drawback of the use of the MSD
platform for NAb assays is the high inter-assay variability;
however the calculated titers for individual samples are
concurrent between assays. The non-cell-based NAb assay is
rapid, completed within a day as opposed to the 2 to 4 days
required for the commonly used antiviral assays or the MxA
protein based assay. The recent introduction of a reportergene assay and a qPCR assay broaden the range of approaches
available to assess the presence of neutralizing antibodies to
IFN-β (Bertolotto et al., 2007; Aarskog et al., 2009; Lallemand
et al., 2008; Lam et al., 2008). While rapid, these assays still
require cell-culture which may not be practical for various
clinical laboratories and can be challenging for assay validation.
The utility of the described non-cell-based NAb assay for
IFN-β is limited as the available assays, including the standard-
ized MxA protein NAb assay, are more sensitive. However, if
utilized, the non-cell-based assay will require validation and
standardization against the MxA protein assay (EMEA/CHMP/
BWP/580136/2007, 2008; Wadhwa et al., in press). While the
use of such assays will be determined on a case-by-case basis,
our study shows that based on the ease of use, rapid assay time,
low matrix interference and the correlation of the NAbs titers
in clinical samples with the titers obtained using cell-based
assays, non-cell-based assays may be potentially valuable
for detection of NAbs for various biotherapeutics, including
therapeutic antibodies.
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